National and Kapodistrian University of Athens
Διερεύνηση και κλινική αξιολόγηση νέων δεικτών μεθυλίωσης του DNA στον καρκίνο, στα πλαίσια της υγρής βιοψίας
Abstract
dc:descriptionLiquid biopsy, based on the analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), provides a non-invasive, real-time monitoring of tumor evolution and therapeutic efficacy. During the last few years, DNA methylation changes have been widely studied, as DNA methylation is considered as an early event in carcinogenesis but is also present at all stages of the disease.In the present PhD thesis, we initially evaluated the preanalytical parameters and the performance of whole genome amplification (WGA) protocols for reliable downstream DNA methylation analyses in liquid biopsy. The present study is the first to evaluate the stability of DNA methylation in plasma and sodium bisulfite (SB)-treated DNA under different storage conditions. Our results indicate that DNA methylation information is not preserved, when ctDNA extraction is performed in plasma samples stored for more than 8 months even at -70℃. On the contrary, SB-treated DNA can be safely stored for a long time at both -20℃ and -70℃, and DNA methylation analysis by real-time MSP can be safely performed in a total period of one year. Concerning the accuracy and precision of WGA of SB-treated DNA our results suggest that it is reliable since we get identical results before and after amplification using both SB-conversion kits. Furthermore, we developed and clinically validated a liquid biopsy-based assay for ESR1 methylation for the follow-up of metastatic breast cancer patients under endocrine treatment. We reported for the first time the presence of ESR1 methylation in CTCs and its high concordance with paired plasma ctDNA derived from the same patients. Moreover, according to our findings, ESR1 methylation in CTCs of hormone receptor-positive metastatic breast cancer patients was strongly associated with lack of response to everolimus/exemestane treatment. We additionally developed and clinically validated an assay for MLL3 promoter methylation as a novel circulating epigenetic biomarker in non-small cell lung cancer (NSCLC). Our data indicate for the first time that the detection of MLL3 promoter methylation in plasma-ctDNA provides important prognostic information for NSCLC patients.Finally, we evaluated the methylation status of tumor-suppressor genes in CTCs of head and neck cancer patients (HNSCC), isolated using the microfluidic-based Parsortix system. SOX17, RASSF1A and MLL3 were found to be methylated in CTCs at various percentages, confirming the presence of heterogeneity, even in CTCs isolated from the same patient.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Mastoraki, Sofia
- Μαστοράκη, Σοφία
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44022